Aiming to Induce Broadly Reactive Neutralizing Antibody Responses with HIV-1 Vaccine Candidates

Overview

Journal Expert Rev Vaccines

Date 2006 Jul 11

PMID 16827619

Citations 47

Authors

Barton F Haynes

David C Montefiori

Affiliations

Soon will be listed here.

Abstract

Neutralizing antibody induction is a key feature of many effective vaccines and is the only immune response that has proven to be capable of completely blocking AIDS virus infection in animal models. Unfortunately, the extensive genetic variability and complex immune-evasion strategies of HIV-1 have thwarted all attempts to date at eliciting an effective neutralizing antibody response with candidate HIV-1 vaccine immunogens. Recent advances in our understanding of how these evasion strategies operate, coupled with growing progress in unravelling the structure and immunobiology of the viral envelope glycoproteins, are contributing to novel immunogen designs to overcome the many barriers to inducing protective antibodies against HIV-1.

Citing Articles

A site of vulnerability at V3 crown defined by HIV-1 bNAb M4008_N1.

Chan K, Luo C, Lu H, Wu X, Kong X Nat Commun. 2021; 12(1):6464.

PMID: 34753944 PMC: 8578649. DOI: 10.1038/s41467-021-26846-z.

Convergent HIV-1 Evolution upon Targeted Destabilization of the gp120-gp41 Interface.

Torrents de la Pena A, Del Moral Sanchez I, Burger J, Bontjer I, Isik G, Eggink D J Virol. 2021; 95(24):e0053221.

PMID: 34586861 PMC: 8610599. DOI: 10.1128/JVI.00532-21.

Development and Evaluation of an Ebola Virus Glycoprotein Mucin-Like Domain Replacement System as a New Dendritic Cell-Targeting Vaccine Approach against HIV-1.

Ao Z, Wang L, Azizi H, Olukitibi T, Kobinger G, Yao X J Virol. 2021; 95(15):e0236820.

PMID: 34011553 PMC: 8274623. DOI: 10.1128/JVI.02368-20.

The breadth of HIV-1 neutralizing antibodies depends on the conservation of key sites in their epitopes.

Bai H, Li Y, Michael N, Robb M, Rolland M PLoS Comput Biol. 2019; 15(6):e1007056.

PMID: 31170145 PMC: 6581281. DOI: 10.1371/journal.pcbi.1007056.

Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice.

Escolano A, Steichen J, Dosenovic P, Kulp D, Golijanin J, Sok D Cell. 2016; 166(6):1445-1458.e12.

PMID: 27610569 PMC: 5019122. DOI: 10.1016/j.cell.2016.07.030.

References

Calarese D, Lee H, Huang C, Best M, Astronomo R, Stanfield R . Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc Natl Acad Sci U S A. 2005; 102(38):13372-7. PMC: 1224641. DOI: 10.1073/pnas.0505763102. View

Mascola J, Sambor A, Beaudry K, Santra S, Welcher B, Louder M . Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. J Virol. 2004; 79(2):771-9. PMC: 538538. DOI: 10.1128/JVI.79.2.771-779.2005. View

B Gilbert P, Ackers M, Berman P, Francis D, Popovic V, Hu D . HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine. J Infect Dis. 2005; 192(6):974-83. DOI: 10.1086/432734. View

Burton D, Desrosiers R, Doms R, Koff W, Kwong P, Moore J . HIV vaccine design and the neutralizing antibody problem. Nat Immunol. 2004; 5(3):233-6. DOI: 10.1038/ni0304-233. View

Takeshita F, Gursel I, Ishii K, Suzuki K, Gursel M, Klinman D . Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9. Semin Immunol. 2004; 16(1):17-22. DOI: 10.1016/j.smim.2003.10.009. View

Mascola J, Lewis M, Stiegler G, Harris D, Vancott T, Hayes D . Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol. 1999; 73(5):4009-18. PMC: 104180. DOI: 10.1128/JVI.73.5.4009-4018.1999. View

LaBranche C, Hoffman T, Romano J, Haggarty B, Edwards T, Matthews T . Determinants of CD4 independence for a human immunodeficiency virus type 1 variant map outside regions required for coreceptor specificity. J Virol. 1999; 73(12):10310-9. PMC: 113086. DOI: 10.1128/JVI.73.12.10310-10319.1999. View

Burton D, Pyati J, Koduri R, Sharp S, Thornton G, Parren P . Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science. 1994; 266(5187):1024-7. DOI: 10.1126/science.7973652. View

Edinger A, Ahuja M, Sung T, Baxter K, Haggarty B, Doms R . Characterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein. J Virol. 2000; 74(17):7922-35. PMC: 112323. DOI: 10.1128/jvi.74.17.7922-7935.2000. View

10.

Garrity R, Rimmelzwaan G, Minassian A, Tsai W, Lin G, de Jong J . Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope. J Immunol. 1997; 159(1):279-89. View

11.

Belshe R, Graham B, Keefer M, Gorse G, Wright P, Dolin R . Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network. JAMA. 1994; 272(6):475-80. DOI: 10.1001/jama.272.6.475. View

12.

McGaughey G, Citron M, Danzeisen R, Freidinger R, Garsky V, Hurni W . HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb. Biochemistry. 2003; 42(11):3214-23. DOI: 10.1021/bi026952u. View

13.

Devico A, Silver A, Thronton A, Sarngadharan M, Pal R . Covalently crosslinked complexes of human immunodeficiency virus type 1 (HIV-1) gp120 and CD4 receptor elicit a neutralizing immune response that includes antibodies selective for primary virus isolates. Virology. 1996; 218(1):258-63. DOI: 10.1006/viro.1996.0188. View

14.

Evans T, Frey S, Israel H, Chiu J, El-Habib R, Gilbert P . Long-term memory B-cell responses in recipients of candidate human immunodeficiency virus type 1 vaccines. Vaccine. 2004; 22(20):2626-30. DOI: 10.1016/j.vaccine.2003.12.011. View

15.

Mascola J . Defining the protective antibody response for HIV-1. Curr Mol Med. 2003; 3(3):209-16. DOI: 10.2174/1566524033479799. View

16.

Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D . Diversity considerations in HIV-1 vaccine selection. Science. 2002; 296(5577):2354-60. DOI: 10.1126/science.1070441. View

17.

Koff W, Johnson P, Watkins D, Burton D, Lifson J, Hasenkrug K . HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol. 2005; 7(1):19-23. DOI: 10.1038/ni1296. View

18.

Su T, Guo B, Wei B, Braun J, Rawlings D . Signaling in transitional type 2 B cells is critical for peripheral B-cell development. Immunol Rev. 2004; 197:161-78. DOI: 10.1111/j.0105-2896.2004.0102.x. View

19.

Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G . A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol. 1993; 67(11):6642-7. PMC: 238102. DOI: 10.1128/JVI.67.11.6642-6647.1993. View

20.

Yang W, Green K, Briones A, Burton D, Barbas 3rd C . CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. J Mol Biol. 1995; 254(3):392-403. DOI: 10.1006/jmbi.1995.0626. View